Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Cancer Res. 2012 Jun 27;72(17):4472–4482. doi: 10.1158/0008-5472.CAN-12-0057

Figure 5. Tumorigenic growth of human pancreatic cancer cells treated with L-NAME.

Figure 5

(A) Mean size ± SEM of subcutaneous tumors derived from CFPac-1 cells in cohorts (n=5) of mice untreated or L-NAME-treated. *P<0.05. (B) Mean size ± SEM of subcutaneous CFPac-1 tumors in cohorts of mice (n=4 to 5) that, upon reaching an established size of 0.75cm3 (arrow), were untreated or treated with L-NAME, gemcitabine, or L-NAME + gemcitabine. P<0.05, *each treatment compared to untreated. (C) The daily mean systolic pressure taken on 26 days over 8 weeks for the cohorts of mice (n=4 to 5) with subcutaneous CFPac-1 tumors that were either untreated or treated with L-NAME, amlodipine, or L-NAME + amlodipine. *P<0.05. ns, non-significant. (D) Mean size ± SEM of CFPac-1 xenografts in animals corresponding to treatment groups described in (C). *P<0.05, L-NAME ± amlodipine compared to untreated.